Lee Integrated Strategies for Drug Discovery Using Mass Spectrometry

1. Auflage 2005
ISBN: 978-0-471-72102-4
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 576 Seiten, E-Book

Reihe: Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods

New strategies and techniques for today's fast-paced discoveryprocess
Today, the pressure is on for high-throughput approaches toaccelerate the generation, identification, and optimization ofmolecules with desirable drug properties. As traditional methods ofanalysis become antiquated, new analytical strategies andtechniques are necessary to meet sample throughput requirements andmanpower constraints. Among them, mass spectrometry has grown to bea front-line tool throughout drug discovery.
Integrated Strategies for Drug Discovery Using Mass Spectrometryprovides a thorough review of current analytical approaches,industry practices, and strategies in drug discovery. The topicsrepresent current industry benchmarks in specific drug discoveryactivities that deal with proteomics, biomarker discovery,metabonomic approaches for toxicity screening, lead identification,compound libraries, quantitative bioanalytical support,biotransformation, reactive metabolite characterization, leadoptimization, pharmaceutical property profiling, sample preparationstrategies, and automation.
THIS BOOK:
* Clearly explains how drug discovery and mass spectrometry areinterconnected
* Discusses the uses and limitations of various types of massspectrometry in various aspects of drug discovery
* Prominently features analytical applications that requiretrace-mixture analysis
* Provides industry applications and real-world examples
* Shares historical background information on various techniques toaid in the understanding of how and why new methods are now beingemployed to analyze samples

Autoren/Hrsg.

Lee, Mike S.

Inhaltsverzeichnis

Preface.
List of Contributors.
Acknowledgements.
1. Miniaturized Formats for Efficient Liquid Chromatography MassSpectrometry-Based Proteomics and Therapeutic Development. (Gary A.Valaskovic and Neil L. Kelleher).
2. Mass-Spectrometry-Based Drug Screening Assays for EarlyPhases in Drug Discovery. (Marshall M. Siegel).
3. ESI-FTICR as a High Throughput Drug Discovery Platform.(Kristin A. Sannes-Lowery, Lendell L. Cummins, Shuo Chen, Jared J.Drader, and Steven A. Hofstadler).
4. Mass Spectrometry- Based Proteomic Approaches for DiseaseDiagnosis and Biomarker Discovery. (Thomas P. Conrads, Haleem J.Issaq, Josi S. Blonder, and Timothy D. Veenstra).
5. Metabonomic Applications in Toxicity Screening and DiseaseDiagnosis. (John P. Shockcor and Elaine Holmes).
6. The Central Role of Mass Spectrometry in Natural ProductsDiscovery. (Jeffrey R. Gilbert, Paul Lewer, Dennis O. Duebelbeis,Andrew W. Carr).
7. Application of Mass Spectrometry to Compound LibraryGeneration, Analysis, and Management. (Xueheng Cheng and JillHochlowski).
8. A Combinatorial Process for Drug Discovery. (David S. Wagner,Richard W. Wagner, Frank Schoenen, and H. Mario Geysen).
9. Application of Technological Advances in BiotransformationStudies. (Carmen L. Fernàndez-Metzler, Raju Subramanian andRichard C. King).
10. Applications of Mass Spectrometry for the Characterizationof Reactive Metabolites of Drugs in Discovery. (Jim Wang, JackWang, Margaret Davis, William DeMaio, JoAnn Scatina, and RasmyTalaat).
11. Advances in High Throughput Quantitative Drug DiscoveryBioanalysis. (Bradley L. Ackermann, Michael J. Berna, and AnthonyT. Murphy).
12. New Strategies for the Implementation and Support ofBioanalysis in a Drug Metabolism Environment. (Walter A.Korfmacher).
13. An Integrated LC-MS Strategy for Preclinical CandidateOptimization. (Jonathan L. Josephs and Mark Sanders).
14. New Approaches for Method Development and Purification inLead Optimization. (Yining Zhao and David J. Semin).
15. High Throughput Metabolic and Physicochemical PropertyAnalysis: Strategies and Tactics for Impact on Drug DiscoverySuccess. (Edward H. Kerns and Li Di).
16. Organ Perfusion and Mass Spectrometry. (C. Gerald Curtis,Ben Chien, David Bar-Or, and Kumar Ramu).
17. Sample Preparation for Drug Discovery Bioanalysis.(David A.Wells).
18. Automation. (John D. Laycock and Thomas Hartmann).
Index.

Über Autor(innen)

MIKE S. LEE, PHD is President of Milestone Development Services. He is actively involved with consulting, workshops, and symposia to connect industry needs with innovative technologies and solutions. His research interests include the applications of mass spectrometry for the analysis of proteins, natural products, drug metabolites, impurities, and degradants. Recent work has involved the development of automated orthogonal control systems for electrospray ionization. Formerly, Dr. Lee was director of analytical research and development at Bristol-Myers Squibb (BMS) Pharmaceutical Research Institute where he led interdisciplinary teams that contributed to the Food and Drug Administration's approval of Buspar® and Serzone, and the accelerated development and approval of TAXOL. Dr. Lee is a member of the American Society of Mass Spectrometry, American Association of Pharmaceutical Scientists, and the American Chemical Society. In addition, he has authored over forty scientific papers and issued patents.